Research and development of a new bioinformatics method to effectively identify the body's own tumors

Copyright © iCell Bioscience Inc, Shanghai 2018-2019

Recently, a research report published in the international journal Cancer Immunology Research, researchers from the Johns Hopkins University School of Medicine developed a new method of using bioinformatics, which can be used as a A new tool helps determine how a patient's immune system responds to cancer immunotherapy and how to effectively identify the body's own tumors.

Researchers hope to get enough data to help clinical researchers determine the best treatment for cancer patients by using a technology called MANAFEST; once someone is diagnosed with cancer, they want to use the technology to develop the most Good treatments, the researchers have not developed MANAFEST technology, and in the past few years, researchers have been able to improve the technology, and now it can analyze multiple data to help effectively treat cancer patients.

Mutation-associated nascent antigens are often used as targets for anti-tumor T cell immunity, but researchers now hope to clarify how T cells recognize MANAs in cancer patients' bodies. To improve the accuracy of bioinformatics data, scientists have changed the way they collect culture media and developed a new technology called FEST analysis (a functional extension of special T cells).

Researchers say the combined information can be used to develop a database that helps researchers discover which types of immunotherapy-related responses are directly related to clinical outcomes, thereby improving the therapeutic benefits of cancer patients; The FEST method can be used to detect specific MANA sequences in blood, tumors, and normal tissues in the patient's body, and it can also be used to predict the response of multiple types of cancer patients to immunotherapy.

Finally, the researchers pointed out that the first-generation FEST technology currently used hopes to collect more data to build a larger database to help monitor the intensity of cancer patients' immune response to disease.